Active Ingredient History
Seladelpar is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Cholangitis, Sclerosing (Phase 2)
Homozygous Familial Hypercholesterolemia (Phase 2)
Hyperlipidemias (Phase 2)
Liver Cirrhosis (Phase 2)
Liver Cirrhosis, Biliary (Phase 3)
Liver Diseases (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue